SLAM and CD31: Signaling molecules involved in cytokine secretion during the development of innate and adaptive immune responses

Cytokine and Growth Factor Reviews

Volumn 18, Issue 1-2, 2007, Pages 85-96

  García, Verónica E ^a   Chuluyan, H Eduardo ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

CD31; Cytokines; Immune response; Signaling proteins; SLAM

Indexed keywords

CD150 ANTIGEN; CD31 ANTIGEN; CYTOKINE;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ARTICLE; CYTOKINE RELEASE; DEVELOPMENT; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD31; AUTOIMMUNITY; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, NATURAL; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 33947276819     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2007.01.008     Document Type: Article

References (79)

1. Latour S., and Veillette A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr Opin Immunol 13 (2001) 299-306
2. Chan A.C., Desai D.M., and Weiss A. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu Rev Immunol 12 (1994) 555-592
3. Watts T.H., and DeBenedette M.A. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol 11 (1999) 286-293
4. Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25 (2005) 9543-9553
5. Chambers C.A., Sullivan T.J., Truong T., and Allison J.P. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur J Immunol 28 (1998) 3137-3143
6. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
7. Akiba H., Miyahira Y., Atsuta M., Takeda K., Nohara C., Futagawa T., et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med 191 (2000) 375-380
8. de Jong E.C., Vieira P.L., Kalinski P., Schuitemaker J.H., Tanaka Y., Wierenga E.A., et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th cell-polarizing signals. J Immunol 168 (2002) 1704-1709
9. Cocks B.G., Chang C.C., Carballido J.M., Yssel H., de Vries J.E., and Aversa G. A novel receptor involved in T-cell activation. Nature 376 (1995) 260-263
10. Nichols K.E., Ma C.S., Cannons J.L., Schwartzberg P.L., and Tangye S.G. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev 203 (2005) 180-199
11. Hsu E.C., Iorio C., Sarangi F., Khine A.A., and Richardson C.D. CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus. Virology 279 (2001) 9-21
12. Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol 6 (2006) 56-66
13. Farina C., Theil D., Semlinger B., Hohlfeld R., and Meinl E. Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. Int Immunol 16 (2004) 799-809
14. Kruse M., Meinl E., Henning G., Kuhnt C., Berchtold S., Berger T., et al. Signaling lymphocytic activation molecule is expressed on mature CD83+ dendritic cells and is up-regulated by IL-1 beta. J Immunol 167 (2001) 1989-1995
15. Bleharski J.R., Niazi K.R., Sieling P.A., Cheng G., and Modlin R.L. Signaling lymphocytic activation molecule is expressed on CD40 ligand-activated dendritic cells and directly augments production of inflammatory cytokines. J Immunol 167 (2001) 3174-3181
16. Velten F.W., Duperrier K., Bohlender J., Metharom P., and Goerdt S. A gene signature of inhibitory MHC receptors identifies a BDCA3(+) subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro. Eur J Immunol 34 (2004) 2800-2811
17. Rethi B., Gogolak P., Szatmari I., Veres A., Erdos E., Nagy L., et al. SLAM/SLAM interactions inhibit CD40-induced production of inflammatory cytokines in monocyte-derived dendritic cells. Blood 107 (2006) 2821-2829
18. Wang N., Satoskar A., Faubion W., Howie D., Okamoto S., Feske S., et al. The cell surface receptor SLAM controls T cell and macrophage functions. J Exp Med 199 (2004) 1255-1264
19. Aversa G., Chang C.C., Carballido J.M., Cocks B.G., and de Vries J.E. Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production. J Immunol 158 (1997) 4036-4044
20. Pasquinelli V., Quiroga M.F., Martinez G.J., Zorrilla L.C., Musella R.M., Bracco M.M., et al. Expression of signaling lymphocytic activation molecule-associated protein interrupts IFN-gamma production in human tuberculosis. J Immunol 172 (2004) 1177-1185
21. Garcia V.E., Quiroga M.F., Ochoa M.T., Ochoa L., Pasquinelli V., Fainboim L., et al. Signaling lymphocytic activation molecule expression and regulation in human intracellular infection correlate with Th1 cytokine patterns. J Immunol 167 (2001) 5719-5724
22. Yamamura M., Uyemura K., Deans R.J., Weinberg K., Rea T.H., Bloom B.R., et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254 (1991) 277-279
23. Isomaki P., Aversa G., Cocks B.G., Luukkainen R., Saario R., Toivanen P., et al. Increased expression of signaling lymphocytic activation molecule in patients with rheumatoid arthritis and its role in the regulation of cytokine production in rheumatoid synovium. J Immunol 159 (1997) 2986-2993
24. Takei M., Ishiwata T., Mitamura K., Fujiwara S., Sasaki K., Nishi T., et al. Decreased expression of signaling lymphocytic-activation molecule-associated protein (SAP) transcripts in T cells from patients with rheumatoid arthritis. Int Immunol 13 (2001) 559-565
25. Castro A.G., Hauser T.M., Cocks B.G., Abrams J., Zurawski S., Churakova T., et al. Molecular and functional characterization of mouse signaling lymphocytic activation molecule (SLAM): differential expression and responsiveness in Th1 and Th2 cells. J Immunol 163 (1999) 5860-5870
26. Latour S., Gish G., Helgason C.D., Humphries R.K., Pawson T., and Veillette A. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol 2 (2001) 681-690
27. Davidson D., Shi X., Zhang S., Wang H., Nemer M., Ono N., et al. Genetic evidence linking SAP, the X-linked lymphoproliferative gene product, to Src-related kinase FynT in T(H)2 cytokine regulation. Immunity 21 (2004) 707-717
28. Sayos J., Wu C., Morra M., Wang N., Zhang X., Allen D., et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395 (1998) 462-469
29. Morra M., Barrington R.A., Abadia-Molina A.C., Okamoto S., Julien A., Gullo C., et al. Defective B cell responses in the absence of SH2D1A. Proc Natl Acad Sci USA 102 (2005) 4819-4823
30. Sayos J., Nguyen K.B., Wu C., Stepp S.E., Howie D., Schatzle J.D., et al. Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4. Int Immunol 12 (2000) 1749-1757
31. Wu C., Nguyen K.B., Pien G.C., Wang N., Gullo C., Howie D., et al. SAP controls T cell responses to virus and terminal differentiation of TH2 cells. Nat Immunol 2 (2001) 410-414
32. Nichols K.E., Koretzky G.A., and June C.H. SAP: natural inhibitor or grand SLAM of T cell activation?. Nat Immunol 2 (2001) 665-666
33. Yin L., Al-Alem U., Liang J., Tong W.M., Li C., Badiali M., et al. Mice deficient in the X-linked lymphoproliferative disease gene sap exhibit increased susceptibility to murine gammaherpesvirus-68 and hypo-gammaglobulinemia. J Med Virol 71 (2003) 446-455
34. Hron J.D., Caplan L., Gerth A.J., Schwartzberg P.L., and Peng S.L. SH2D1A regulates T-dependent humoral autoimmunity. J Exp Med 200 (2004) 261-266
35. Latour S., Roncagalli R., Chen R., Bakinowski M., Shi X., Schwartzberg P.L., et al. Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation. Nat Cell Biol 5 (2003) 149-154
36. Chan B., Lanyi A., Song H.K., Griesbach J., Simarro-Grande M., Poy F., et al. SAP couples Fyn to SLAM immune receptors. Nat Cell Biol 5 (2003) 155-160
37. Quiroga M.F., Martinez G.J., Pasquinelli V., Costas M.A., Bracco M.M., Malbran A., et al. Activation of signaling lymphocytic activation molecule triggers a signaling cascade that enhances Th1 responses in human intracellular infection. J Immunol 173 (2004) 4120-4129
38. Wu C., Sayos J., Wang N., Howie D., Coyle A., and Terhorst C. Genomic organization and characterization of mouse SAP, the gene that is altered in X-linked lymphoproliferative disease. Immunogenetics 51 (2000) 805-815
39. Howie D., Okamoto S., Rietdijk S., Clarke K., Wang N., Gullo C., et al. The role of SAP in murine CD150 (SLAM)-mediated T-cell proliferation and interferon gamma production. Blood 100 (2002) 2899-2907
40. Meroni L., Fusi M.L., Varchetta S., Biasin M., Rusconi S., Villa M.L., et al. Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and redirection of HIV-specific responses via SLAM triggering. Clin Immunol 92 (1999) 276-284
41. Carballido J.M., Aversa G., Kaltoft K., Cocks B.G., Punnonen J., Yssel H., et al. Reversal of human allergic T helper 2 responses by engagement of signaling lymphocytic activation molecule. J Immunol 159 (1997) 4316-4321
42. Ferrante P., Fusi M.L., Saresella M., Caputo D., Biasin M., Trabattoni D., et al. Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J Immunol 160 (1998) 1514-1521
43. Newman P.J. The biology of PECAM-1. J Clin Invest 100 (1997) S25-S29
44. Elias III C.G., Spellberg J.P., Karan-Tamir B., Lin C.H., Wang Y.J., McKenna P.J., et al. Ligation of CD31/PECAM-1 modulates the function of lymphocytes, monocytes and neutrophils. Eur J Immunol 28 (1998) 1948-1958
45. Treutiger C.J., Heddini A., Fernandez V., Muller W.A., and Wahlgren M. PECAM-1/CD31, an endothelial receptor for binding Plasmodium falciparum-infected erythrocytes. Nat Med 3 (1997) 1405-1408
46. Deaglio S., Morra M., Mallone R., Ausiello C.M., Prager E., Garbarino G., et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 160 (1998) 395-402
47. Prager E., Sunder-Plassmann R., Hansmann C., Koch C., Holter W., Knapp W., et al. Interaction of CD31 with a heterophilic counterreceptor involved in downregulation of human T cell responses. J Exp Med 184 (1996) 41-50
48. Albelda S.M., Oliver P.D., Romer L.H., and Buck C.A. EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol 110 (1990) 1227-1237
49. Tang D., Chen Y., Newman P., Shi L., Gao X., Diglio C., et al. Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J Biol Chem 268 (1993) 22883-22894
50. Lutzky V.P., Carnevale R.P., Alvarez M.J., Maffia P.C., Zittermann S.I., Podhajcer O.L., et al. Platelet-endothelial cell adhesion molecule-1 (CD31) recycles and induces cell growth inhibition on human tumor cell lines. J Cell Biochem 98 (2006) 1334-1350
51. Romer L., McLean N., Yan H., Daise M., Sun J., and DeLisser H. IFN-g and TNF-a induce redistribution of PECAM-1 (CD31) on human endothelial cells. J Immunol 154 (1995) 6582-6592
52. Rival Y., Maschio A.D., Rabiet M., Dejana E., and Duperray A. Inhibition of platelet endothelial cell adhesion molecule-1 synthesis and leukocyte transmigration in endothelial cells by the combined action of TNF-a and IFN-g. J Immunol 157 (1996) 1233-1241
53. Mamdouh Z., Chen X., Pierini L.M., Maxfield F.R., and Muller W.A. Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature 421 (2003) 748-753
54. Muro S., Wiewrodt R., Thomas A., Koniaris L., Albelda S.M., Muzykantov V.R., et al. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 2003 116 (2003) 1599-1609
55. Sandoval I., and Bakke O. Targeting of membrane proteins to endosome and lysosomes. Trends Cell Biol 4 (1994) 292-297
56. Kirchhausen T., Bonifacino J.S., and Riezman H. Linking cargo to vesicle formation: receptor tail interactions with coat proteins. Curr Opin Cell Biol 9 (1997) 488-495
57. Liao F., Ali J., Greene T., and Muller W.A. Soluble domain 1 of platelet-endothelial cell adhesion molecule (PECAM) is sufficient to block transendothelial migration in vitro and in vivo. J Exp Med 185 (1997) 1349-1357
58. Pinter E., Barreuther M., Lu T., Imhof B.A., and Madri J.A. Platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) tyrosine phosphorylation state changes during vasculogenesis in the murine conceptus. Am J Pathol 150 (1997) 1523-1530
59. DeLisser H.M., Christofidou-Solomidou M., Strieter R.M., Burdick M.D., Robinson C.S., Wexler R.S., et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151 (1997) 671-677
60. Newman P.J. Switched at birth: a new family for PECAM-1. J Clin Invest 103 (1999) 5-9
61. Ilan N., and Madri J.A. PECAM-1: old friend, new partners. Curr Opin Cell Biol 15 (2003) 515-524
62. Newman P. Switched at birth: a new family for PECAM-1. J Clin Invest 103 (1999) 5-9
63. Newton-Nash D.K., and Newman P.J. A new role for platelet-endothelial cell adhesion molecule-1 (CD31): inhibition of TCR-mediated signal transduction. J Immunol 163 (1999) 682-688
64. Newton-Nash D., and Newman P. A new role for platelet-endothelial cell adhesion molecule-1(CD31): inhibition of TCR-mediated signal transduction. J Immunol 163 (1999) 682-688
65. Berman M., and Muller W. Ligation of platelet/endothelial cell adhesion molecule 1 (PECAM-1/CD31) on monocytes and neutrophils increases binding capacity of leukocyte CR3 (CD11b/CD18). J Immunol 154 (1995) 299-307
66. Berman M.E., Xie Y., and Muller W.A. Roles of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in natural killer cell transendothelial migration and beta 2 integrin activation. J Immunol 156 (1996) 1515-1524
67. Nelissen I., Ronsse I., Van Damme J., and Opdenakker G. Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta. J Leukoc Biol 71 (2002) 89-98
68. Gao C., Sun W., Christofidou-Solomidou M., Sawada M., Newman D.K., Bergom C., et al. PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosis. Blood 102 (2003) 169-179
69. Ferrero E., Belloni D., Contini P., Foglieni C., Ferrero M.E., Fabbri M., et al. Transendothelial migration leads to protection from starvation-induced apoptosis in CD34+CD14+ circulating precursors: evidence for PECAM-1 involvement through Akt/PKB activation. Blood 101 (2003) 186-193
70. Ilan N., Mohsenin A., Cheung L., and Madri J.A. PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics. FASEB J 15 (2001) 362-372
71. Scimone M.L., Lutzky V.P., Zittermann S.I., Maffia P., Jancic C., Buzzola F., et al. Migration of polymorphonuclear leucocytes is influenced by dendritic cells. Immunology 114 (2005) 375-385
72. Masuda M., Osawa M., Shigematsu H., Harada N., and Fujiwara K. Platelet endothelial cell adhesion molecule-1 is a major SH-PTP2 binding protein in vascular endothelial cells. FEBS Lett 408 (1997) 331-336
73. Ilan N., Cheung L., Pinter E., and Madri J.A. Platelet-endothelial cell adhesion molecule-1 (CD31), a scaffolding molecule for selected catenin family members whose binding is mediated by different tyrosine and serine/threonine phosphorylation. J Biol Chem 275 (2000) 21435-21443
74. Saito T. Negative regulation of T cell activation. Curr Opin Immunol 10 (1998) 313-321
75. Prager E., Staffler G., Majdic O., Saemann M., Godar S., Zlabinger G., et al. Induction of hyporesponsiveness and impaired T lymphocyte activation by the CD31 receptor:ligand pathway in T cells. J Immunol 166 (2001) 2364-2371
76. Demeure C.E., Byun D.G., Yang L.P., Vezzio N., and Delespesse G. CD31X (PECAM-1) is a differentiation antigen lost during human CD4 T-cell maturation into Th1 or Th2 effector cells. Immunology 88 (1996) 110-115
77. Newman P.J., and Newman D.K. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol 23 (2003) 953-964
78. Torimoto Y., Rothstein D.M., Dang N.H., Schlossman S.F., and Morimoto C. CD31, a novel cell surface marker for CD4 cells of suppressor lineage, unaltered by state of activation. J Immunol 148 (1992) 388-396
79. Carrithers M., Tandon S., Canosa S., Michaud M., Graesser D., and Madri J.A. Enhanced susceptibility to endotoxic shock and impaired STAT3 signaling in CD31-deficient mice. Am J Pathol 166 (2005) 185-196